14 automated systems accelerating organoid maturation in 2026 The first quarter of 2026 has ushered in a regulatory milestone as the European Medicines Agency (EMA) formally integrates 3D-bioprinted tissue validation into its standard drug toxicity protocols. This policy shift is forcing a rapid transition away from traditional animal testing, particularly in the oncology and hepatology sectors...